These findings suggest that mefatinib effectively and non-selectively inhibits various subtypes of EGFR-mutant lung cancer resulting in similar clinical benefits for patients regardless of EGFR sensitizing mutation types. The gene discussed is EGFR; the disease is lung carcinoma.